Atara Biotherapeutics (ATRA) Treasury Shares (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Treasury Shares came in at $322690.0 in Q1 2026, down 52.4% YoY from $677948.0 in Q1 2025, and up 49.36% on a QoQ basis from $216048.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Treasury Shares (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Treasury Shares data on file, last reported at $322690.0 in Q1 2026.
- Quarterly Treasury Shares fell 52.4% year-over-year to $322690.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $322690.0 (down 52.4% YoY) and the FY2025 annual result came in at $216048.0, down 47.87% from the prior year.
- Treasury Shares rose to $322690.0 in Q1 2026, from $216048.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $16.5 million in Q1 2024 to a low of $216048.0 in Q4 2025.
- A 5-year average of $4.7 million and a median of $677948.0 in 2025 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2023 — Treasury Shares plunged 96.26% — and 2024, when it soared 65.32%.
- Tracing ATRA's Treasury Shares over 5 years: stood at $6.7 million in 2022, then sank by 96.26% to $250709.0 in 2023, then soared by 65.32% to $414470.0 in 2024, then sank by 47.87% to $216048.0 in 2025, then surged by 49.36% to $322690.0 in 2026.
- The last three Treasury Shares figures came in at $322690.0 (Q1 2026), $216048.0 (Q4 2025), and $278347.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 2.72 Mn |
| 10 | Atara Biotherapeutics | 143.41 Mn | 126.86 Mn | 439,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 384,839.00 |
| Jun 30, 2026 | 384,839.00 |
| Mar 31, 2026 | 322,690.00 |
| Mar 31, 2026 | 322,690.00 |
| Dec 31, 2025 | 216,048.00 |
| Dec 31, 2025 | 216,048.00 |
| Sep 30, 2025 | 278,347.00 |
| Sep 30, 2025 | 278,347.00 |
| Jun 30, 2025 | 503,640.00 |
| Jun 30, 2025 | 503,640.00 |
| Mar 31, 2025 | 677,948.00 |
| Mar 31, 2025 | 677,948.00 |
| Dec 31, 2024 | 414,470.00 |
| Dec 31, 2024 | 414,470.00 |
| Sep 30, 2024 | 517,400.00 |
| Sep 30, 2024 | 517,400.00 |
| Jun 30, 2024 | 554,938.00 |
| Jun 30, 2024 | 554,938.00 |
| Mar 31, 2024 | 16.47 Mn |
| Mar 31, 2024 | 16.47 Mn |